Identifying important comorbidity among cancer populations using administrative data: Prevalence and impact on survival

Asia-Pacific Journal of Clinical Oncology

Volumn 12, Issue 1, 2016, Pages e47-e56

  Sarfati, Diana ^a   Gurney, Jason ^a   Lim, Bee Teng ^a   Bagheri, Nasser ^a   Simpson, Andrew ^b   Koea, Jonathan ^c   Dennett, Elizabeth ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

Cancer; Comorbidity; Prevalence estimate; Survival outcome

Indexed keywords

ADULT; AGED; COMORBIDITY; FEMALE; HUMAN; MIDDLE AGED; NEOPLASMS; NEW ZEALAND; PREVALENCE; PROPORTIONAL HAZARDS MODEL; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS; NEW ZEALAND; PREVALENCE; PROPORTIONAL HAZARDS MODELS;

EID: 84890535373     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12130     Document Type: Article

References (49)

1. Ogle KS, Swanson GM, Woods N, Azzouz F. Cancer and comorbidity: redefining chronic diseases. Cancer 2000; 88 (3): 653-663.
2. Coebergh JW, Janssen-Heijnen ML, Razenberg PP. Prevalence of co-morbidity in newly diagnosed patients with cancer: a population-based study. Crit Rev Oncol Hematol 1998; 27 (2): 97-100.
3. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 2000; 35 (3): 181-200.
4. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL, Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291 (20): 2441-2447.
5. Sarfati D, Tan L, Blakely T, Pearce N. Comorbidity among patients with colon cancer. NZ Med J 2011; 124 (1338): 76-88.
6. Yancik R, Havlik RJ, Wesley MN etal. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 1996; 6 (5): 399-412.
7. Sarfati D. Review of methods to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol 2012; 65: 924-933.
8. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care 2006; 44 (10): 921-928.
9. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care 2002; 40 (8 Suppl.): 26-35.
10. Charlson M. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: a response. J Clin Epidemiol 1993; 46 (10): 1083-1084.
11. Deyo R. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: a response. J Clin Epidemiol 1993; 46 (10): 1081-1082.
12. Quan H, Sundararajan V, Halfon P etal. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43 (11): 1130-1139.
13. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993; 46 (10): 1075-1079.
14. Coebergh JW, Janssen-Heijnen ML, Post PN, Razenberg PP. Serious co-morbidity among unselected cancer patients newly diagnosed in the southeastern part of The Netherlands in 1993-1996. J Clin Epidemiol 1999; 52 (12): 1131-1136.
15. Janssen-Heijnen MLG, Houterman S, Lemmens VEPP, Louwman MWJ, Maas HAAM, Coebergh JWW. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol 2005; 55 (3): 231-240.
16. Klabunde CN, Legler JM, Warren JL, Baldwin L-M, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007; 17 (8): 584-590.
17. Piccirillo JF, Costas I, Claybour P, Borah A, Gorove L, Jeffe D. The measurement of comorbidity by cancer registries. J Reg Mgmt 2003; 30 (1): 8-14.
18. Zeber JE, Copeland LA, Hosek BJ, Karnad AB, Lawrence VA, Sanchez-Reilly SE. Cancer rates, medical comorbidities, and treatment modalities in the oldest patients. Crit Rev Oncol Hematol 2008; 67 (3): 237-242.
19. Adami HO, Hunter D, Trichopoulos D. Textbook of Cancer Epidemiology. Oxford University Press, 2nd edn. New York 2008.
20. Extermann M. Interaction between comorbidity and cancer. Cancer Control 2007; 14 (1): 13-22.
21. Tabares-Seisdedos R, Dumont N, Baudot A etal. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol 2011; 12 (6): 604-608.
22. Flossmann E, Rothwell PM, Doctors Aspirin B, Uktiaat T. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369 (9573): 1603-1613.
23. Driver JA, Kurth T, Buring JE, Gaziano JM, Logroscino G. Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease. Cancer Causes Control 2007; 18 (7): 705-711.
24. Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer disease and cancer. Neurology 2005; 64 (5): 895-898.
25. West AB, Dawson VL, Dawson TM. To die or grow: Parkinson's disease and cancer. Trends Neurosci 2005; 28 (7): 348-352.
26. Blanco JAG, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martin IJG. Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing 2008; 37 (6): 715-718.
27. Koppie TM, Serio AM, Vickers AJ etal. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112 (11): 2384-2392.
28. Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA. Multiple informants: a new method to assess breast cancer patients′ comorbidity. Am J Epidemiol 2003; 157 (3): 249-257.
29. Newschaffer CJ, Penberthy LT, Desch CE, Retchin SM, Whittemore M. The effect of age and comorbidity in the treatment of elderly women with nonmetastatic breast cancer. Arch Intern Med 1996; 156 (1): 85-90.
30. Sarfati D, Hill S, Blakely T etal. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer 2009; 9: 116-125.
31. Tammemagi C, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 2005; 294 (14): 1765-1772.
32. Cronin-Fenton DP, Norgaard M, Jacobsen J etal. Comorbidity and survival of Danish breast cancer patients from 1995 to 2005. Br J Cancer 2007; 96 (9): 1462-1468.
33. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29 (10): 1335-1341.
34. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care 1999; 37 (6): 601-614.
35. Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D. The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 2011; 103 (14): 1101-1111.
36. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994; 120 (2): 104-110.
37. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer 2003; 103 (6): 792-802.
38. Young J, Roffers F, Gloeckler Ries L, Fritz A. SEER Summary Staging Manual - 2000: Codes and Coding Instructions. National Cancer Institute, Bethesda, MD 2000.
39. Charlson M, Pompei P, Ales K, Mackenzie C. A new method for classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
40. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36 (1): 8-27.
41. Colinet B, Jacot W, Bertrand D etal. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index. Br J Cancer 2005; 93 (10): 1098-1105.
42. Fleming ST, Pearce KA, McDavid K, Pavlov D. The development and validation of a comorbidity index for prostate cancer among Black men. J Clin Epidemiol 2003; 56 (11): 1064-1075.
43. Holman CD, Preen DB, Baynham NJ, Finn JC, Semmens JB. A multipurpose comorbidity scoring system performed better than the Charlson index. J Clin Epidemiol 2005; 58 (10): 1006-1014.
44. Sarfati D, Hill S, Purdie G, Dennett E, Blakely T. How well does routine hospitalisation data capture information on comorbidity in New Zealand? NZ Med J 2010; 123 (1310): 50-61.
45. Piccirillo JF, Vlahiotis A, Barrett LB, Flood KL, Spitznagel EL, Steyerberg EW. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008; 67 (2): 124-132.
46. Gross CP, Guo Z, McAvay GJ, Allore HG, Young M, Tinetti ME. Multimorbidity and survival in older persons with colorectal cancer. J Am Geriatr Soc 2006; 54 (12): 1898-1904.
47. Kieszak SM, Flanders WD, Kosinski AS, Shipp CC, Karp H. A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol 1999; 52 (2): 137-142.
48. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol 1996; 156 (1): 127-132.
49. Read WL, Tierney RM, Page NC etal. Differential prognostic impact of comorbidity. J Clin Oncol 2004; 22 (15): 3099-3103.